These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 17520065)

  • 21. Recommendations for harmonization of data collection and analysis of developmental neurotoxicity endpoints in regulatory guideline studies: Proceedings of workshops presented at Society of Toxicology and joint Teratology Society and Neurobehavioral Teratology Society meetings.
    Li AA; Sheets LP; Raffaele K; Moser V; Hofstra A; Hoberman A; Makris SL; Garman R; Bolon B; Kaufmann W; Auer R; Lau E; Vidmar T; Bowers WJ
    Neurotoxicol Teratol; 2017 Sep; 63():24-45. PubMed ID: 28757310
    [TBL] [Abstract][Full Text] [Related]  

  • 22. International STakeholder NETwork (ISTNET): creating a developmental neurotoxicity (DNT) testing road map for regulatory purposes.
    Bal-Price A; Crofton KM; Leist M; Allen S; Arand M; Buetler T; Delrue N; FitzGerald RE; Hartung T; Heinonen T; Hogberg H; Bennekou SH; Lichtensteiger W; Oggier D; Paparella M; Axelstad M; Piersma A; Rached E; Schilter B; Schmuck G; Stoppini L; Tongiorgi E; Tiramani M; Monnet-Tschudi F; Wilks MF; Ylikomi T; Fritsche E
    Arch Toxicol; 2015 Feb; 89(2):269-87. PubMed ID: 25618548
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Developmental neurotoxicity guideline study: issues with methodology, evaluation and regulation.
    Tsuji R; Crofton KM
    Congenit Anom (Kyoto); 2012 Sep; 52(3):122-8. PubMed ID: 22925212
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of the developmental neurotoxicity of compounds by measuring locomotor activity in zebrafish embryos and larvae.
    Selderslaghs IW; Hooyberghs J; Blust R; Witters HE
    Neurotoxicol Teratol; 2013; 37():44-56. PubMed ID: 23357511
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The potential of mechanistic information organised within the AOP framework to increase regulatory uptake of the developmental neurotoxicity (DNT) in vitro battery of assays.
    Sachana M; Willett C; Pistollato F; Bal-Price A
    Reprod Toxicol; 2021 Aug; 103():159-170. PubMed ID: 34147625
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human Oligodendrocytes and Myelin In Vitro to Evaluate Developmental Neurotoxicity.
    Chesnut M; Hartung T; Hogberg H; Pamies D
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360696
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design and validation of an ontology-driven animal-free testing strategy for developmental neurotoxicity testing.
    Hessel EVS; Staal YCM; Piersma AH
    Toxicol Appl Pharmacol; 2018 Sep; 354():136-152. PubMed ID: 29544899
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Knowledge sharing to facilitate regulatory decision-making in regard to alternatives to animal testing: Report of an EPAA workshop.
    Ramirez T; Beken S; Chlebus M; Ellis G; Griesinger C; De Jonghe S; Manou I; Mehling A; Reisinger K; Rossi LH; van Benthem J; van der Laan JW; Weissenhorn R; Sauer UG
    Regul Toxicol Pharmacol; 2015 Oct; 73(1):210-26. PubMed ID: 26188116
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An expert-driven literature review of "negative" chemicals for developmental neurotoxicity (DNT) in vitro assay evaluation.
    Martin MM; Baker NC; Boyes WK; Carstens KE; Culbreth ME; Gilbert ME; Harrill JA; Nyffeler J; Padilla S; Friedman KP; Shafer TJ
    Neurotoxicol Teratol; 2022; 93():107117. PubMed ID: 35908584
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A better approach to in vivo developmental neurotoxicity assessment: Alignment of rodent testing with effects seen in children after neurotoxic exposures.
    Vorhees CV; Sprowles JN; Regan SL; Williams MT
    Toxicol Appl Pharmacol; 2018 Sep; 354():176-190. PubMed ID: 29544898
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Towards in vitro DT/DNT testing: Assaying chemical susceptibility in early differentiating NT2 cells.
    Menzner AK; Abolpour Mofrad S; Friedrich O; Gilbert DF
    Toxicology; 2015 Dec; 338():69-76. PubMed ID: 26498558
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Omnisphero: a high-content image analysis (HCA) approach for phenotypic developmental neurotoxicity (DNT) screenings of organoid neurosphere cultures in vitro.
    Schmuck MR; Temme T; Dach K; de Boer D; Barenys M; Bendt F; Mosig A; Fritsche E
    Arch Toxicol; 2017 Apr; 91(4):2017-2028. PubMed ID: 27722930
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Developmental neurotoxicity testing: a path forward.
    Crofton KM; Mundy WR; Shafer TJ
    Congenit Anom (Kyoto); 2012 Sep; 52(3):140-6. PubMed ID: 22925214
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Meeting report: Validation of toxicogenomics-based test systems: ECVAM-ICCVAM/NICEATM considerations for regulatory use.
    Corvi R; Ahr HJ; Albertini S; Blakey DH; Clerici L; Coecke S; Douglas GR; Gribaldo L; Groten JP; Haase B; Hamernik K; Hartung T; Inoue T; Indans I; Maurici D; Orphanides G; Rembges D; Sansone SA; Snape JR; Toda E; Tong W; van Delft JH; Weis B; Schechtman LM
    Environ Health Perspect; 2006 Mar; 114(3):420-9. PubMed ID: 16507466
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human Ntera2 cells as a predictive in vitro test system for developmental neurotoxicity.
    Stern M; Gierse A; Tan S; Bicker G
    Arch Toxicol; 2014 Jan; 88(1):127-36. PubMed ID: 23917397
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A critical evaluation of the 2011 ECHA reports on compliance with the REACH and CLP regulations and on the use of alternatives to testing on animals for compliance with the REACH regulation.
    Spielmann H; Sauer UG; Mekenyan O
    Altern Lab Anim; 2011 Oct; 39(5):481-93. PubMed ID: 22103941
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current status of developmental neurotoxicity: an industry perspective.
    Kaufmann W
    Toxicol Lett; 2003 Apr; 140-141():161-9. PubMed ID: 12676463
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Implementation challenges for designing integrated in vitro testing strategies (ITS) aiming at reducing and replacing animal experimentation.
    De Wever B; Fuchs HW; Gaca M; Krul C; Mikulowski S; Poth A; Roggen EL; Vilà MR
    Toxicol In Vitro; 2012 Apr; 26(3):526-34. PubMed ID: 22269383
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Re-evaluation of animal numbers and costs for in vivo tests to accomplish REACH legislation requirements for chemicals - a report by the transatlantic think tank for toxicology (t(4)).
    Rovida C; Hartung T
    ALTEX; 2009; 26(3):187-208. PubMed ID: 19907906
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro developmental neurotoxicity (DNT) testing: relevant models and endpoints.
    Bal-Price AK; Hogberg HT; Buzanska L; Lenas P; van Vliet E; Hartung T
    Neurotoxicology; 2010 Sep; 31(5):545-54. PubMed ID: 19969020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.